Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP

European Journal of Medicinal Chemistry(2022)10.1016/j.ejmech.2022.114407Source: DataRank Database

Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP is a research paper published in European Journal of Medicinal Chemistry (2022). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.71)OA: greenTopics (64)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Fangrui Wu ORCID,Jingyu Wu ORCID,Xin Li ORCID,Chao Zhou ORCID,Yuan Yao ORCID

Live enrichment

PubMed:35512565 PMC:PMC9165588 OpenAlex:https://openalex.org/W4224926712

National Cancer Institute

Grant: R01CA266057

Cancer Prevention and Research Institute of Texas

Grant: RP180177

U.S. Army Medical Research Acquisition Activity

Grant: W81XWH-18-1-0368

National Institutes of Health

Grant: 5R01CA266057-04

Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia

U.S. Department of Defense

National Institutes of Health

FWCI

0.71

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9165588

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/9165588

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9165588

publisherhttps://api.elsevier.com/content/article/PII:S0223523422003099?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0223523422003099?httpAccept=text/plain

Fields of Study

Histone Deacetylase Inhibitors ResearchGenomics and Chromatin DynamicsEpigenetics and DNA MethylationMedicineChemistry0301 basic medicine03 medical and health sciences0303 health sciencesAcetylationAcetyltransferasesEnzyme InhibitorsHistone AcetyltransferasesHistonesHumansLysineNeoplasmsPyrazinesStructure-Activity Relationship

MeSH Terms

AcetylationAcetyltransferasesEnzyme InhibitorsHistonesHumansLysineNeoplasmsPyrazinesStructure-Activity RelationshipHistone Acetyltransferases

Keywords

AcetylationHistone acetyltransferaseHistone AcetyltransferasesChemistryHistoneLysineAcetyltransferaseP300-CBP Transcription FactorsStructure–activity relationshipBiochemistryEnzymePyrazineCancer researchGeneAmino acidStereochemistryBiologyIn vitroCancer therapyP300/cbpSmall-molecule InhibitorMedical SciencesBiophysics610HistonesStructure-Activity RelationshipAcetyltransferasesNeoplasmsMedical SpecialtiesMedicine and Health SciencesHumansEnzyme InhibitorsLife Sciences540Pyrazinesand Structural Biology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP

FAIR Checklist

Authors (7)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)